Get startedLog in
    Picture of UCB SA logo

    UCB — UCB SA News Story

    0.000.00%
    be flag iconLast trade - 00:00
    HealthcareAdventurousLarge CapHigh Flyer
    All News

    Brief: UCB Presents New Data On Investigational Therapy For Thymidine Kinase 2 Deficiency

    Picture of UCB SA logoUCB SA
    19/03/2025 07:59
    March 19 (Reuters) - Ucb SA UCB.BR:

NEW DATA ON INVESTIGATIONAL THERAPY FOR THYMIDINE KINASE 2 DEFICIENCY PRESENTED AT MUSCULAR DYSTROPHY ASSOCIATION (MDA) 2025 CONFERENCE

CLINICAL DATA HIGHLIGHT SURVIVAL BENEFITS, IMPROVEMENT IN FUNCTIONAL MOTOR OUTCOMES ASSOCIATED WITH TREATMENT WITH DOXECITINE (DC) AND DOXRIBTIMINE (DT) IN PEOPLE LIVING WITH THYMIDINE KINASE 2 DEFICIENCY (TK2D)

Source text: [ID:]

Further company coverage: UCB.BR

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

    Recent news on UCB SA

    See all news